Werewolf Therapeutics (HOWL) Projected to Post Earnings on Tuesday

Werewolf Therapeutics (NASDAQ:HOWL) is expected to announce its Q4 2025 results before the market opens on Tuesday, March 10th. Analysts expect Werewolf Therapeutics to post earnings of ($0.35) per share for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Wednesday, March 18, 2026 at 9:30 AM ET.

Werewolf Therapeutics Stock Performance

Shares of HOWL stock opened at $0.63 on Monday. The company has a current ratio of 3.87, a quick ratio of 3.87 and a debt-to-equity ratio of 0.73. Werewolf Therapeutics has a 12 month low of $0.53 and a 12 month high of $2.38. The firm has a market capitalization of $30.67 million, a PE ratio of -0.39 and a beta of 0.78. The firm has a fifty day simple moving average of $0.64 and a two-hundred day simple moving average of $1.08.

Insiders Place Their Bets

In other news, Director Luke Evnin sold 108,606 shares of Werewolf Therapeutics stock in a transaction dated Monday, December 29th. The shares were sold at an average price of $0.61, for a total value of $66,249.66. Following the completion of the transaction, the director owned 2,550,674 shares in the company, valued at $1,555,911.14. This trade represents a 4.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Insiders have sold a total of 857,809 shares of company stock worth $601,350 in the last three months. 23.60% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Marshall Wace LLP purchased a new stake in shares of Werewolf Therapeutics during the second quarter worth $113,000. Jane Street Group LLC bought a new stake in shares of Werewolf Therapeutics during the 2nd quarter valued at $409,000. Renaissance Technologies LLC lifted its holdings in Werewolf Therapeutics by 48.6% during the 4th quarter. Renaissance Technologies LLC now owns 677,766 shares of the company’s stock worth $429,000 after purchasing an additional 221,766 shares in the last quarter. Bank of America Corp DE boosted its stake in Werewolf Therapeutics by 1.2% in the 2nd quarter. Bank of America Corp DE now owns 2,129,024 shares of the company’s stock worth $2,321,000 after purchasing an additional 25,882 shares during the period. Finally, Vanguard Group Inc. boosted its stake in Werewolf Therapeutics by 8.5% in the 3rd quarter. Vanguard Group Inc. now owns 1,408,047 shares of the company’s stock worth $2,774,000 after purchasing an additional 109,796 shares during the period. 64.84% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on HOWL. HC Wainwright cut their target price on Werewolf Therapeutics from $10.00 to $4.00 and set a “buy” rating on the stock in a research report on Friday, December 19th. Citigroup downgraded shares of Werewolf Therapeutics from a “market outperform” rating to a “market perform” rating in a research report on Friday, December 19th. Weiss Ratings reissued a “sell (d-)” rating on shares of Werewolf Therapeutics in a research report on Wednesday, January 21st. Zacks Research lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, November 21st. Finally, Citizens Jmp lowered Werewolf Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Friday, December 19th. Two investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $3.75.

About Werewolf Therapeutics

Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company’s proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.

Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.